Can Regeneron Squeeze Another Use Out Of Blockbuster Hopeful Dupixent? [Investor's Business Daily]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Investors Business Daily
Related news Regeneron Pharmaceuticals ( REGN ) jumped Tuesday after its blockbuster hopeful Dupixent showed promise in treating nasal polyps. In afternoon trading on the stock market today , Regeneron stock popped 4.9%, near 396.20. Regeneron stock is forming a flat base with a buy point at 416.59. Shares of biotech companies as a group spiked 3.2%, reversing from a double-digit pullback this month. The study pitted Dupixent against a placebo in treating nasal polyps in patients suffering chronic sinus infections. This could be the third use for Dupixent, Leerink analyst Geoffrey Porges said. It had Food and Drug Administration approval as an eczema treatment and is under consideration as an asthma drug. But Porges noted Dupixent faces adoption hurdles in treating nasal polyps. Dupixent costs about $36,000 a year and is a biweekly injection. Nasal polyps generally are treated with corticosteroids or nasal surgery. "To the extent some of these patients are identified and in the care
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) [Yahoo! Finance]Yahoo! Finance
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)GlobeNewswire
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution [Yahoo! Finance]Yahoo! Finance
- Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)GlobeNewswire
REGN
Earnings
- 2/2/24 - Beat
REGN
Sec Filings
- 4/3/24 - Form 4
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- REGN's page on the SEC website